Exosomes in Parkinson's Disease: Current Perspectives and Future Challenges

ACS Chem Neurosci. 2019 Feb 20;10(2):964-972. doi: 10.1021/acschemneuro.8b00469. Epub 2019 Feb 1.

Abstract

Exosomes, which are lipid bilayer membrane vesicles, have been implicated as carriers of biological macromolecules. In recent years, the functions of exosomes in the spreading of pathological conversion of proteins among neurons have drawn particular attention in Parkinson's disease research. Extracellular α-synuclein is proven to be associated with exosomes in vivo and in vitro. The contents of these exosomes may be altered during the pathological and clinical processes, serving as a potential target for biomarker development in Parkinson's disease. This Review highlights the current understanding of biogenesis and pathophysiological roles of exosomes. Meanwhile, exosomes are promising delivery vehicles. Artificial exosomes can be loaded with defined therapeutically active molecules, such as drugs, small interfering RNAs, long noncoding RNAs, and proteins to the brain, ensuring the site-specific targeting strategy to the recipient cells. Therefore, we will also discuss the potential applications of exosomes in developing modified exosome-based drug carrier systems to halt the pathologic propagation of Parkinson's disease.

Keywords: Exosomes; Parkinson’s disease; α-synuclein.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Brain / drug effects
  • Brain / metabolism
  • Drug Carriers / administration & dosage*
  • Drug Carriers / metabolism*
  • Exosomes / metabolism*
  • Forecasting
  • Humans
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism*
  • alpha-Synuclein / metabolism*

Substances

  • Biomarkers
  • Drug Carriers
  • alpha-Synuclein